S. aureus, enterotoxins ID'd in atopic keratoconjunctivitis

S. aureus enterotoxins ID'd in atopic keratoconjunctivitis

(HealthDay) -- Staphylococcus aureus (S. aureus) and S. aureus-secreted enterotoxins (SE) are frequently found in patients with atopic keratoconjunctivitis (AKC), particularly in those with corneal ulceration, according to a study published online April 10 in Allergy.

Hiroshi Fujishima, M.D., from the Tsurumi University School of in Yokohama, Japan, and colleagues enrolled 18 individuals with AKC, nine with vernal keratoconjunctivitis (VKC), eight with seasonal allergic (SAC), and 10 healthy volunteers to investigate the role of SE in the pathophysiology of AKC. Participants underwent slit lamp examinations, including fluorescein staining. Samples were collected from the skin around the eyelid margins, lower conjunctival sacs, and upper tarsal conjunctiva. Superantigen (SAg) genes were identified using assays.

The researchers found that, compared with VKC patients, SAC patients, and healthy volunteers, S. aureus was detected significantly more in AKC patients. In 11 patients, SAg genes were identified and included SEB (two of 11), SEG (eight of 11), and SEI (eight of 11). SE detection varied significantly between AKC and SAC patients. SE was detected in significantly more patients with corneal ulcers (six of 10) than in patients without corneal ulcers (two of 17).

"S. aureus and SE were frequently found in association with corneal ulceration, suggesting a pathogenic role in the development of ulcers in AKC," the authors conclude.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Steroids could help heal some corneal ulcers

Oct 18, 2011

A UCSF study gives hope to those suffering from severe cases of bacterial corneal ulcers, which can lead to blindness if left untreated. The use of topical corticosteroids in a randomized controlled trial was found to be ...

Recommended for you

ERS: Mepolizumab is glucocorticoid-sparing in asthma

Sep 09, 2014

(HealthDay)—For patients with eosinophilic asthma, mepolizumab has a glucocorticoid-sparing effect and reduces exacerbations when administered intravenously or subcutaneously, according to two studies published ...

User comments